Annalisa Citro

Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience

Carmine Liberatore, Virginia Valeria Ferretti, Paola Tacchetti, Concetta Conticello et autres

it (code pays fourni par la source)

Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data

Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, Roberta Della Pepa et autres

it, jp, us, gr, gb (code pays fourni par la source)

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Paola Stefanoni et autres

it (code pays fourni par la source)

Author response for "Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study"

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Paola Stefanoni et autres

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi et autres

it, jp, us (code pays fourni par la source)

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi et autres

it (code pays fourni par la source)

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Carmine Liberatore, Paola Tacchetti, Concetta Conticello, Gregorio Barilà et autres

it (code pays fourni par la source)

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, Diana Giannarelli, Loredana Pettine et autres

it (code pays fourni par la source)

Chronic Myeloid Leukemia With P190 BCR-ABL Translocation and Persistent Moderate Monocytosis: A Case Report.

Arianna Gatti, Alessandra Movilia, Lucia Roncoroni, Annalisa Citro et autres

it (code pays fourni par la source)

Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant

Francesco Spina, Vittorio Montefusco, Claudia Crippa, Annalisa Citro et autres

it (code pays fourni par la source)

Evaluation of the Impact of Three Different Pre-Transplant Strategies On the Outcome of Myeloma Patients Candidates to High-Dose Therapy.

Alessandro Corso, Silvia Mangiacavalli, Luciana Barbarano, Annalisa Citro et autres

it (code pays fourni par la source)

A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis.

Antonio Palumbo, Federica Cavallo, Dina Ben Yehuda, Paola Omedè et autres

it, il (code pays fourni par la source)